

Topiramate for essential tremor [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2017, Issue 4".]

Table of contents

Abstract

Plain language summary

Background

- Description of the condition

- Description of the intervention

- How the intervention might work

- Why it is important to do this review

Objectives

Methods

- Criteria for considering studies for this review

- Search methods for identification of studies

- Data collection and analysis

Results

- Description of studies

- Risk of bias in included studies

- Effects of interventions

Discussion

- Summary of main results

- Overall completeness and applicability of evidence

- Quality of the evidence

- Potential biases in the review process

- Agreements and disagreements with other studies or reviews

Authors' conclusions

Acknowledgements

Data and analyses

Contributions of authors

Declarations of interest

Sources of support

- Internal sources

- External sources

Differences between protocol and review

Notes

Characteristics of studies

- Characteristics of included studies [ordered by study ID]

References

- References to studies included in this review

Editors: Cochrane [Unknown]

Corresponding author: Elisa Bruno (e.bruno@hotmail.it)

Department GF Ingrassia, Section of Neurosciences, University of Catania, Catania, 95123, Italy

Elisa Bruno [¹]Alessandra Nicoletti [¹]Graziella Quattrocchi [¹]Roberta Allegra [²]Graziella Filippini [³]

Carlo Colosimo [⁴]Mario Zappia [¹]

[1] Department GF Ingrassia, Section of Neurosciences,
University of Catania, Catania, Italy

[2] Department of Neurological Sciences, Policlinico
Universitario G. Martino Messina, Messina, Italy

[3] Scientific Direction, Fondazione IRCCS, Istituto
Neurologico Carlo Besta, Milan, Italy

[4] Department of Neurology, Terni University Hospital,
Terni, Italy

Citation

Bruno E, Nicoletti A, Quattrocchi G, Allegra R, Filippini G, Colosimo C, Zappia M. Topiramate for essential tremor [Data only. When citing this record quote "Cochrane Database of Systematic Reviews 2017, Issue 4"]. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: . DOI: .

Dates

Revision published: Issue TBD, TBD (TBD)

Version published (citation changed): Issue TBD, TBD (TBD)

Review first published: Issue TBD, TBD

Protocol first published: N/A

Abstract

Background

Objectives

Search methods

Selection criteria

Data collection and analysis

Main results

Authors' conclusions

Plain language summary

Use of topiramate for the treatment of essential tremor

Review question

The authors of this review tried to assess the effectiveness and safety of topiramate in people with essential tremor.

Background

Essential tremor is a type of uncontrollable shaking or trembling of parts of the body. Although it is not harmful in terms of its effect on life expectancy, it generally gets worse and may be disabling. Treatment is usually with medicines (called propranolol and primidone), which may not work in a quarter to a half of people with essential tremor. Some specialists have suggested that another medicine, topiramate, could be useful for treating the condition.

Study characteristics

We searched medical databases for studies of topiramate compared with placebo (a pretend tablet) or any other medicine in adults with essential tremor. We found three studies comparing topiramate versus placebo, involving 309 participants with moderate to severe essential tremor.

Key results

The effect of topiramate on daily activities, risk of stopping treatment and side effects was uncertain because the quality of evidence was very low to low.

Quality of evidence

We only found a few studies that had problems with their methods so we could not make firm conclusions about how well topiramate works and if it has side effects.

Background

Description of the condition

Description of the intervention

How the intervention might work

Why it is important to do this review

Objectives

Methods

Criteria for considering studies for this review

Types of studies

Types of participants

Types of interventions

Types of outcome measures

Primary outcomes

Secondary outcomes

Search methods for identification of studies

Electronic searches

Searching other resources

Data collection and analysis

Selection of studies

Data extraction and management

Assessment of risk of bias in included studies

Measures of treatment effect

Unit of analysis issues

Dealing with missing data

Assessment of heterogeneity

Assessment of reporting biases

Data synthesis

Subgroup analysis and investigation of heterogeneity

Sensitivity analysis

Results

Description of studies

Results of the search

Included studies

Excluded studies

Risk of bias in included studies

Allocation

Blinding

Incomplete outcome data

Selective reporting

Other potential sources of bias

Effects of interventions

Discussion

Summary of main results

Overall completeness and applicability of evidence

Quality of the evidence

Potential biases in the review process

Agreements and disagreements with other studies or reviews

Authors' conclusions

Implications for practice

Implications for research

Acknowledgements

Data and analyses

Comparison 1

Topiramate versus placebo/open control

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1.1 Functional disability component related to tremor	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only	
1.1.1 Change in TRSS subscale B score	1	208	Mean Difference (IV, Fixed, 95% CI)	-5.40 [-8.42, -2.38]	
1.1.2 Change	1	208	Mean Difference (IV, Fixed, 95% CI)	-5.70 [-8.74, -2.66]	

Outcome or subgroup title		No. of studies	No. of participants	Statistical method	Effect size	
	1.1.3					
	1.2					
	1.2.1					
	1.2.1 With dra wals: lack of effi c					
	1.1.3 Change in TRS to tal score	3	273	Mean Difference (IV, Fixed, 95% CI)	-8.91 [-10.50, -7.33]	
	1.2 With dra wals	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only	
	1.2.1 With dra wals: lack of effi c	2	285	Risk Ratio (M-H, Fixed, 95% CI)	0.18 [0.02, 1.53]	

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
	1. 2. 2 With dra wals: A E s	285	Risk Ratio (M-H, Fixed, 95% CI)	3.17 [1.79, 5.63]	
	1. 2. 3 With dra wals: ot her re as ons	285	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.45, 2.05]	
1. 2. 4 With dra wals: to tal	285	Risk Ratio (M-H, Fixed, 95% CI)	1.78 [1.23, 2.60]		

Contributions of authors

Declarations of interest

Sources of support

Internal sources

- No sources of support provided

External sources

- No sources of support provided

Differences between protocol and review

Notes

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Carrasco Vargas 2011

<i>Study characteristics</i>	
Methods	
Participants	
Interventions	
Outcomes	
Notes	

Connor 2008

<i>Study characteristics</i>	
Methods	
Participants	
Interventions	
Outcomes	
Notes	

Ondo 2006

<i>Study characteristics</i>	
Methods	
Participants	
Interventions	
Outcomes	
Notes	

References


References to studies included in this review

Carrasco Vargas 2011 {published data only}

Connor 2008 {published data only}

Ondo 2006 {published data only}

Analysis 1.1



Analysis 1.2

